The effect of aging on OX40 agonist-mediated cancer immunotherapy

Cancer Immunology, Immunotherapy

Volumn 58, Issue 12, 2009, Pages 1941-1947

  Ruby, Carl E ^a   Weinberg, Andrew D ^a  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

Author keywords

Aging; Co stimulation; OX40

Indexed keywords

CD134 ANTIGEN;

AGING; ANIMAL; DRUG POTENTIATION; EXPERIMENTAL NEOPLASM; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; MOUSE; REVIEW; T LYMPHOCYTE;

AGING; ANIMALS; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS, EXPERIMENTAL; RECEPTORS, OX40; T-LYMPHOCYTES;

EID: 79958125217     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0687-6     Document Type: Conference Paper

References (54)

1. Akiba H et al (2000) Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J Exp Med 191:375-380 (Pubitemid 30060926)
2. Arch RH et al (2000) Translocation of TRAF proteins regulates apoptotic threshold of cells. Biochem Biophys Res Commun 272:936-945 (Pubitemid 30420738)
3. Atanackovic D et al (2004) Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 172:3289-3296 (Pubitemid 38263721)
4. Brocker T et al (1999) CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles. Eur J Immunol 29:1610-1616 (Pubitemid 29224466)
5. Cheever MA, Creekmore S (eds) (2007) National Cancer Institute agent workshop proceedings. http://web.ncifcrf.gov/research/brb/ workshops.asp
6. Clise-Dwyer K et al (2007) Environmental and intrinsic factors lead to antigen unresponsiveness in CD4(+) recent thymic emigrants from aged mice. J Immunol 178:1321-1331 (Pubitemid 46154602)
7. Coley WB (1891) Contribution to the knowledge of sarcoma. Ann Surg 14:199-220
8. Compaan DM, Hymowitz SG (2006) The crystal structure of the costimulatory OX40-OX40L complex. Structure 14:1321-1330 (Pubitemid 44176375)
9. Croft M (2003) Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 3:609-620
10. Dominguez AL, Lustgarten J (2008) Implications of aging and self-tolerance on the generation of immune and antitumor immune responses. Cancer Res 68:5423-5431
11. Effros RB, Walford RL (1983) The immune response of aged mice to influenza: diminished T-cell proliferation, interleukin 2 production and cytotoxicity. Cell Immunol 81:298-305 (Pubitemid 13017143)
12. Evans DE et al (2001) Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4. J Immunol 167:6804-6811 (Pubitemid 33144171)
13. Ewel CH et al (1992) Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects. Cancer Res 52:3005-3010
14. Fujita T et al (2006) Functional characterization of OX40 expressed on human CD8+ T cells. Immunol Lett 106:27-33 (Pubitemid 44093048)
15. Gough MJ et al (2008) OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res 68:5206-5215
16. Gramaglia I et al (2000) The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol 165:3043-3050
17. Gramaglia I et al (1998) Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 161:6510-6517 (Pubitemid 28562188)
18. Grolleau-Julius A et al (2006) Effect of aging on bone marrow-derived murine CD11c+ CD4-CD8alpha-dendritic cell function. J Gerontol A Biol Sci Med Sci 61:1039-1047 (Pubitemid 44727211)
19. Haynes L, Eaton SM (2005) The effect of age on the cognate function of CD4+ T cells. Immunol Rev 205:220-228 (Pubitemid 40780188)
20. Kaleeba JA et al (1998) The OX-40 receptor provides a potent co-stimulatory signal capable of inducing encephalitogenicity in myelin-specific CD4+ T cells. Int Immunol 10:453-461 (Pubitemid 28182102)
21. Kawamata S et al (1998) Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation. J Biol Chem 273:5808-5814 (Pubitemid 28124057)
22. Kjaergaard J et al (2000) Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res 60:5514-5521
23. Krieg AM (2007) Development of TLR9 agonists for cancer therapy. J Clin Invest 117:1184-1194
24. Kuriyama H et al (2006) Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination. Cell Immunol 243:30-40 (Pubitemid 46275615)
25. Lee SW et al (2006) Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses. J Immunol 177:4464-4472
26. Li SP et al (2002) Early antigen-specific response by naive CD8 T cells is not altered with aging. J Immunol 168:6120-6127 (Pubitemid 34620029)
27. Linton PJ et al (1997) From naive to effector-alterations with aging. Immunol Rev 160:9-18
28. Linton PJ et al (2005) Intrinsic versus environmental influences on T-cell responses in aging. Immunol Rev 205:207-219
29. Lustgarten J et al (2004) Aged mice develop protective antitumor immune responses with appropriate costimulation. J Immunol 173:4510-4515 (Pubitemid 39280681)
30. Maxwell JR et al (2000) Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol 164:107-112 (Pubitemid 30012979)
31. Mittler JN, Lee WT (2004) Antigen-specific CD4 T cell clonal expansion and differentiation in the aged lymphoid microenvironment. I. The primary T cell response is unaffected. Mech Ageing Dev 125:47-57 (Pubitemid 38045326)
32. Murata K et al (2002) Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases. J Immunol 169:4628-4636 (Pubitemid 35178243)
33. Ohshima Y et al (1997) Expression and function of OX40 ligand on human dendritic cells. J Immunol 159:3838-3848 (Pubitemid 127469639)
34. Prins RM et al (2006) The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol 176:157-164 (Pubitemid 43023259)
35. Redmond WL et al (2007) Defects in the acquisition of CD8 T Cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J Immunol 179:7244-7253
36. Ruby CE et al (2008) IL-12 is required for anti-OX40-mediated CD4 T cell survival. J Immunol 180:2140-2148
37. Ruby CE et al (2007) Anti-OX40 stimulation in vivo enhances CD8(+) memory T cell survival and significantly increases recall responses. Eur J Immunol 37:157-166 (Pubitemid 46128796)
38. Ruby CE, Weinberg AD (2009) OX40-enhanced tumor rejection and effector T cell differentiation decreases with age. J Immunol 182:1481-1489
39. Salek-Ardakani S, Croft M (2006) Regulation of CD4 T cell memory by OX40 (CD134). Vaccine 24:872-883 (Pubitemid 43185302)
40. Sharma S et al (2008) CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged. Cancer Immunol Immunother 57:549-561 (Pubitemid 351170538)
41. Shurin GV et al (2004) Regulation of dendritic cell expansion in aged athymic nude mice by FLT3 ligand. Exp Gerontol 39:339-348 (Pubitemid 38264364)
42. So T, Croft M (2007) Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+ Foxp3+ T cells. J Immunol 179:1427-1430
43. Song A et al (2007) Cooperation between CD4 and CD8 T cells for anti-tumor activity is enhanced by OX40 signals. Eur J Immunol 37:1224-1232 (Pubitemid 46925307)
44. Takeda I et al (2004) Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol 172:3580-3589 (Pubitemid 38337939)
45. Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133-146
46. Trinchieri G, Sher A (2007) Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 7:179-190
47. Valzasina B et al (2005) Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105:2845-2851 (Pubitemid 40446278)
48. Vu MD et al (2007) OX40 costimulation turns off Foxp3+ Tregs. Blood 110:2501-2510 (Pubitemid 47523172)
49. Watford WT et al (2003) The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 14:361-368 (Pubitemid 37099449)
50. Watts TH (2005) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23:23-68
51. Weinberg AD et al (2000) Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 164:2160-2169 (Pubitemid 30108775)
52. Weinberg AD et al (2006) Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J Immunother 29:575-585 (Pubitemid 44674041)
53. Weinberg AD et al (1998) OX-40: life beyond the effector T cell stage. Semin Immunol 10:471-480 (Pubitemid 28564376)
54. Weinberg AD et al (1999) Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol 162:1818-1826 (Pubitemid 29307063)